due to the lifelong difference in HDL cholesterol levels; disease however, this difference is a consequence of having the Y chromosome. During fetal development, the Y chromoOn average, women develop heart disease some 10-15 some directs the formation of testes rather than ovaries, years later than men. This raises the question of whether and the testes in turn produce testosterone and dihydrotesthere is some aspect of 'femaleness' which reduces risk, or tosterone rather than estrone and estradiol as the primary whether there is some aspect of 'maleness' that raises risk. sex steroids [6] . The high levels of male sex hormones To date, most attention has been focused on the hypothesis drive down the HDL cholesterol levels, with consequent that endogenous estrogen is cardioprotective in women [1] .
even more gaps in our knowledge about the real effects of lower risk is found in those who have recently started testosterone than there are for estrogen. As in the case of estrogen as well as in long-term users [16] . estrogen, clinical trials with hard endpoints using anThese findings from observational epidemiology provide drogens, androgen antagonists, or selective androgen rethe rationale for clinical trials testing whether and to what ceptor modulators will ultimately be needed to resolve this degree current use of postmenopausal hormone therapy issue, but it is difficult to anticipate that such trials will be prevents a first heart attack. However, the observational done in the near future.
epidemiology is not sufficient to prove the case, because The statement that CHD rates in women rise steeply even the best studies may be subject to a variety of after the age of menopause, and the corollary that this is systematic biases that could lead to an overestimation of due to lower levels of estrogen after that age, is also open benefit and an underestimation of harm from hormone to question. In actuality, there is no evidence for an therapy, hence the need for an unbiased estimate from increase in the year-on-year rate of increase in CHD clinical trials. These biases in observational studies include around the age of menopause. The linear relationship healthy user selection bias, compliance bias, surveillance between age and CHD incidence as seen on a semilogaritbias, and survivor bias [14, 17] . hmic plot shows that there is a constant proportional
In combination, these biases will lead to a systematic increase in CHD incidence with age, with no inflection overestimation of benefit, and an underestimation of risk in upward at the average age of menopause [14] . This is observational studies. Adjusting for baseline differences in evidence for an age effect, and evidence against an effect risk factors will mitigate healthy user selection bias, but of menopause. The Nurses' Health Study investigators will not correct for compliance, surveillance, or survivor have reported that, after controlling for age and smoking bias. Thus, the real benefit for CHD may be much less than status, the natural menopause is not associated with an predicted by the observational studies, or there may be no increased risk for CHD [2] . The same investigators have benefit at all [14] . The clinical trials to date have failed to reported that, in contrast to the natural menopause, bilatershow overall benefit for CHD over the short term (ongoing al oophorectomy is associated with an increased risk for trials will ascertain the long term effects particularly in CHD in women who had never taken estrogen after women without prevalent CHD) [18] . menopause. However, the study had very few cases of CHD in women with oophorectomy, and the increased risk was no longer significant in the multivariate analysis. Nonetheless, the use of estrogens appeared to eliminate 3. Biological mechanisms for cardioprotection by this increased risk. It is possible that women who have a estrogen hysterectomy and bilateral oophorectomy (often done for menorrhagia / metrorrhagia associated with endometrial
The possibility that estrogen may reduce CHD risk has hyperplasia) are at higher risk for CHD because of the stimulated a wide variety of studies that attempt to explain co-existence of metabolic risk factors such as central the presumed benefit. Because it was unexpected, fewer obesity, high blood pressure, lipid disorders, and glucose studies have been done to explain the apparent excess risk intolerance. The finding of an apparent lower risk in early in the course of treatment, found in recent clinical women who subsequently used estrogen would be subject trials (see below). Effects of estrogen that may predict to the biases discussed below. In summary, the postbenefit include: lowered LDL cholesterol and lipoprotein menopausal increase in risk is most likely due to age and (a) levels, raised HDL cholesterol levels, reduced fibrinonot the menopause, and the increase in risk in women after gen levels and enhanced fibrinolysis (reduced plasminogen oophorectomy may be due to confounding by other risk activator inhibitor-1 (PAI-1) and increased D-dimer levels), factors.
reduced homocysteine levels, antioxidant properties, and improved endothelial function (e.g. reduced E-selectin levels and enhanced flow-mediated dilatation) [1] . Estrogen and progesterone reduce lipid accumulation in 2. Observational studies of estrogen users macrophages from female, but not male, donors [19] . On the other hand, several mechanisms that might increase By far the most persuasive evidence in favor of a risk after estrogen administration have been found: triprotective effect for estrogen comes from the large number glycerides increase, some coagulation markers increase of cohort studies comparing CHD risk in postmenopausal (e.g. Factor VII, prothrombin fragments 112, activated women currently using estrogen to never-users. These protein C resistance), and the inflammatory marker Cstudies have shown consistently that CHD risk is 35-50% reactive protein increases [20] [21] [22] [23] . Some observational lower in estrogen users, after adjusting for other risk studies have suggested that certain of the lipid markers factors [15, 16] . The lower risk has been found in studies of changed by estrogen administration are associated with estrogen alone, as well as in studies of estrogen in higher relative risks for CHD in women than in men, combination with a progestin [16] . For healthy women, the including HDL cholesterol and triglycerides [23, 24] . How-ever, particularly in respect of coagulation and inflamma-4. Genetic mechanisms for cardioprotection by tion, laboratory measurements do not predict whether the estrogen predominant effect will be favorable or unfavorable.
Studies of venous thromboembolism (including clinical
The role of the major monogenic disorders such as trials) provide unequivocal evidence that the overall effect familial hypercholesterolemia and familial hyperis indeed procoagulant [25, 26] .
homocysteinemia in arterial disease is well established.
Compounding this difficulty in interpreting laboratory
Even within kindreds with familial hypercholesterolemia, measurements is the fact that progestins counteract some affected females develop CHD later than in males, preof the estrogen effects, and that the clinical expression of sumably because the same (unknown) factors that delay metabolic changes may be time-dependent. The early onset in non-affected females continue to operate in excess risk for arterial disease observed in the Heart and affected females [38] . Though estrogen administration Estrogen / Progestin Replacement Study (HERS) may have lowers LDL cholesterol in women with familial hyperbeen due to an initial procoagulant or inflammatory effect cholesterolemia [39] , this pharmacologic property does not on susceptible plaques, while the favorable effects in the necessarily mean that endogenous estrogen has the same survivors may be due to the later assertion of the generally effect. There is no sex difference in the elevated LDL favorable lipid effects [27] . In HERS, participants with cholesterol levels of individuals with familial hypercholeshigher levels at baseline had the largest decrease in terolemia [38] . Rather, as in non-affected individuals, lipoprotein (a) on treatment, and had a more favorable factors that blunt the impact of a given level of LDL clinical outcome than participants with lower baseline cholesterol in females (or accelerate it in males) need to be levels [28] . The role of estrogen's direct vascular effect is sought. unclear, since impaired endothelial function has not yet
The importance to arterial disease of polymorphisms in been established as a risk factor for CHD. Interestingly, the genes that code for coagulation proteins and markers of current estrogen users do not appear to have a lower risk inflammation is not clear. For example, a variety of for angina, as one would expect if direct vascular effects polymorphisms in the fibrinogen gene are known to affect were important [16] . On the other hand, in a clinical trial circulating fibrinogen levels, and fibrinogen levels have sublingual estrogen relieved exercise-induced angina [29] .
been associated with arterial disease [40] . However, Overall, the studies of mechanisms have not resolved the studies seeking to quantify the association of a fibrinogen core issue of whether estrogens protect against CHD.
gene polymorphism with arterial disease have generally It is important to realize that almost all the studies of yielded disappointing results. This may be because any mechanism used oral estrogen preparations, and may turn individual polymorphism has a modest influence on fibrinout to have little relevance towards explaining the gender ogen levels, and the levels are simultaneously affected by difference in CHD. Ovarian estrogen directly enters the both other genetic factors, and importantly, by environsystemic circulation through the inferior vena cava, unlike mental factors [40] . Hence, it is difficult to discern the oral estrogens, which enter the portal vein and undergo direct effect of any individual polymorphism on clinical first pass hepatic circulation. Because of extensive metabodisease. In addition to fibrinogen, polymorphisms in the lism in the liver, in order to achieve similar blood levels genes for FVII, FXIII, FV, prothrombin, thrombomodulin, the dose of oral estrogen needs to be approximately ten tissue plasminogen activator, PAI-1, and platelet-memtimes that of non-oral (e.g transdermal) estrogen. These brane glycoproteins have been described [40] . Except for doses of estrogens profoundly influence the hepatic metabfibrinogen, the relationships of the phenotypic factors olism of a variety of proteins, including lipid apoproteins, affected by these polymorphisms with arterial disease are coagulation proteins, and (probably) C-reactive protein uncertain. A possible interaction of gender with poly-[20-22, [30] [31] [32] [33] [34] . The large effects on lipids and coagulation morphisms in the FVII gene has been described, in that proteins described for oral estrogens are greatly attenuated, plasma activity of FVII in males varies markedly accordabsent, or in the opposite direction with non-oral estrogens.
ing to the presence of three of these polymorphisms, but in Non-oral estrogens have very modest effects on lowering females these polymorphisms are associated with much LDL-cholesterol and lipoprotein (a), have no effect or smaller changes in FVII activity [41] . Estrogen affects reduce triglycerides, have no effect on HDL-cholesterol, many of these phenotypic factors [20] [21] [22] [32] [33] [34] [35] , but in and have a modest or no effect on levels of coagulation general it is not known whether there is a protective or proteins [30] [31] [32] [33] [34] . Non-oral estrogens retain the ability to harmful interaction of estrogen with the polymorphisms as improve endothelial function [35] . Additional mechanistic risk factors for arterial disease. studies, as well as epidemiologic studies and clinical trials, Both males and females have a-and b-estrogen rethat focus on the role of non-oral estrogen preparations are ceptors in the vascular endothelium, smooth muscle, and needed. Of interest, epidemiologic studies in postmyocardium, though receptor numbers may be higher in menopausal women have not shown an association of females because estrogen induces their expression [1, 42] . endogenous estrogen levels with CHD [36, 37] .
One group of investigators found a gender difference for the non-genomic effects of estrogen on the response of causing the harm. It remains possible that the lipid changes coronary arteries to acetylcholine. Males did not show the induced by HRT may result in long-term benefit for reversal of acetylcholine-induced vasoconstriction in corwomen who survive the first years. This question remains onary arteries after acute estrogen administration found in unanswered at this point, but for many women the answer females [43] . On the other hand, genetic males receiving may be moot if ways of avoiding the early harm are not long-term estrogen therapy show enhanced flow-mediated found. dilatation [44] . The presence of higher numbers of functional estrogen receptors in females may relate to the inhibition of injury-induced vascular intimal thickening by 6. Mechanisms for explaining an increased risk for estrogen in female arteries, and the lower prevalence of left arterial disease shortly after commencing HRT ventricular hypertrophy in women compared to men [1, 45, 46] . Estrogen receptor numbers are lower in female Hypotheses for explaining early harm center around a atherosclerotic arteries [46] . There is some potential for potential interaction of HRT with coagulation and / or polymorphisms of the estrogen receptors themselves to inflammation mechanisms in a subset of women with affect the clinical outcome of estrogen administration. For vulnerable plaques. According to these hypotheses, expoexample, the common ER Pvu II and Xbal genotypes are sure to HRT for certain women with a susceptibility factor not associated with differences in HDL cholesterol levels, in the form of an elevated blood or tissue level, or with an but after estrogen administration women who are heteroaugmented response to HRT perhaps due to a genetic zygous for the genotype have a greater elevation of HDL mutation, may result in plaque destabilization and thromcholesterol [47] . The clinical relevance of this finding is bosis. unknown.
HRT induces a wide variety of changes in coagulation factors in healthy women. Some of these are likely to be procoagulant, while others are likely to profibrinolytic,
Evidence of early harm from clinical trials
hence the clinical effect cannot be predicted from laboratory studies. Because of an emphasis on a few factors, in The evidence emerging from trials of hormone replaceparticular reductions in levels of fibrinogen and PAI-1, ment therapy (HRT) to prevent coronary heart disease many scientists believed that HRT exerted a favorable (CHD) continues to confound the belief that HRT is effect on coagulation. As noted above, clinical trials and cardioprotective. On the contrary, a fairly consistent epidemiologic studies confirm that the net effect of HRT is pattern of early harm is emerging from secondary and, to a to promote coagulation in the venous system [25, 26] . lesser extent, from primary prevention trials. Long term There is a growing suspicion that coagulation factors effects of HRT on the cardiovascular system, and also on beyond platelets may be more important in arterial disease the overall health of postmenopausal women, are being than previously appreciated. Among the coagulation mechevaluated in the ongoing primary prevention trials [18] .
anisms the Factor V Leiden (FVL) mutation and the The findings from four clinical trials of HRT in women prothrombin G20210A mutation are currently of most are consistent with an early excess of arterial cardiovascuinterest for both venous and arterial disease. lar events: HERS, the Papworth HRT and Atherosclerosis FVL produces a coagulation factor V which resists the Survival Enquiry (PHASE), the Women's Estrogen for action of the major natural anticoagulant, activated protein Stroke Trial (WEST), and the Women's Health Initiative C. Hence, the phenotypic expression can be measured as (WHI) [27, [48] [49] [50] . In addition, a combined analysis of activated protein C (APC) resistance. The prevalence of short-term trials (typically lasting a year) in healthy heterozygous FVL in whites is about 4.8% (range 3-7%), women showed a non-significant 39% excess risk for CHD with a much lower prevalence of 0.05% in Blacks and [51] . Support for short-term harm comes also from the Asians [57] . FVL is associated with venous thromboemboearly trials in men, and several observational studies of lism (VTE), and is found in about 18% of unselected cases new users of HRT among women with prior CHD [52] [53] [54] [55] of VTE and about 40% of selected cases with presumed and one of healthy women in the Group Health Cofamilial thrombophilia. The risk for VTE associated with operative study [56] . The evidence comes from secondary FVL is amplified by exposure to oral contraceptives (OCs) and primary prevention trials, trials using conjugated and the risk associated with APC resistance is amplified by equine estrogens (CEE) with and without medroxyproges-HRT use [57] [58] [59] . In contrast, the association of FVL with terone (MPA), and trials of estradiol (oral and transder-CHD has not been found in men, and in women it has been mal). Many of the trials have weaknesses (and in the case inconsistent [60] [61] [62] [63] . In a case-control study of younger of WHI the data have not been published); individually women, FVL was associated with MI in those with other their findings can be rationalized away, but in aggregate risk factors for CHD, particularly smoking [62] . However, the findings are persuasive. Therefore, the question is no two other case-control studies in women failed to show an longer whether the early harm is real, but rather what is association with CHD, or an interaction with HRT use [60, 65] . In one cross-sectional study of women referred to On the other hand, for women who survive the acute phase a lipid clinic for management of dyslipidemia, HRT use in or who do not have vulnerable plaques, the long-term the absence of FVL was associated with a reduced risk for effect of elevated levels of MMP-9 might be favorable, atherothrombotic arterial disease, while HRT use in the since the proteinases might prevent the accumulation of presence of FVL was associated with an increased risk matrix proteins and improve arterial compliance. [63] . Thus, the status of FVL as a risk factor for CHD is These intriguing observations and hypotheses have great much less certain than for VTE, and only one study potential relevance to women, as they affect the future use suggested an interaction with HRT. On the other hand, of exogenous estrogens in the form of HRT. It is unknown there is insufficient data to exclude a possible role for FVL whether endogenous estrogens affect these markers of in CHD in women, particularly in the context of CHD inflammation and coagulation, and therefore unknown associated with HRT use.
whether these factors have a role in explaining the gender The prothrombin G20210A mutation is procoagulant difference in cardiovascular disease. If anything, the because it increases prothrombin levels. The prevalence is known and suspected interactions of estrogen with these lower than FVL, being found in about 2.7% of whites markers go against the observation of delayed onset in (range 1-4%). As for FVL, the prevalence is much lower women, since they raise the risk for arterial disease in in Blacks and Asians (0.06%) [57] . It is associated with women. Younger women may have higher rates of VTE VTE, being found in 7% of unselected cases and 16% of events than men, but it is not known whether endogenous selected cases of VTE. In women, but not in men, the estrogen or use of oral contraceptives explain that observamutation has been found to be associated with CHD tion [72] . [64] [65] [66] [67] . A cross-sectional analysis of women with dyslipidemia found that the HRT use was associated with decreased risk for atherothrombotic disease in the absence 7. Conclusions of the G20210A mutation, and increased risk in its presence [66] . A case-control study of non-fatal MI in
The gender difference in the age of onset of CHD is as women with hypertension (a parallel study of women yet unexplained. A natural starting point is that the without hypertension was negative) found that presence of biologic effects of the XX and XY chromosomes are the mutation alone was associated with an odds ratio for expressed through sex hormones, and that these explain the MI of 1.5 (95% CI 0.6-1.4) and current use of HRT alone gender difference in CHD. However, the respective roles was associated with an odds ratio of 0.9 (0.3-7.7) [64] .
of female and male sex hormones in this regard remain However, the presence of both the mutation and use of unclear. To date, research has focused overwhelmingly on HRT was associated with an odds ratio of 10.9 (2.2-55.2, estrogen. The substantial evidence in favor of a protective P50.002). This supra-multiplicative effect of the comeffect of estrogen in women is being called into question bined factors represents true synergism. If confirmed, a by recent clinical trial data indicating that HRT is not large synergistic effect between HRT and a prothrombotic protective, and at least in women with existing heart factor in the range of 3-5% could explain the pattern of disease may initially increase risk. Because of the inearly harm and late benefit seen in the HERS trial [64] .
creased in risk in secondary prevention trials, and the HRT also affects several markers of inflammation, some absence of published clinical trial data for primary prevenin a potentially unfavorable direction and some in a tion, HRT is no longer being recommended for prevention potentially favorable direction. HRT increases circulating of CHD [73] . It remains possible that HRT given for many levels of C-reactive protein and matrix metalloproteinases years may be cardioprotective. including matrix metalloproteinase-9 (MMP-9) [22, 68, 69] .
Oral estrogen has pronounced effects on blood markers On the other hand, HRT decreases circulating levels of cell and cell function, including endothelial cells and monoadhesion molecules E-selectin, intercellular adhesion cyte-derived macrophages. Some of these effects may be molecule-1, and vascular cell adhesion molecule-1, and in favorable, others unfavorable, and thus laboratory studies the short term improves endothelial function [70, 71] . An cannot predict clinical outcomes. Clinical trials indicate intriguing hypothesis put forward by Cannon. et al. centers that the net effect of estrogen is prothrombotic. The on the effects of estrogen on MMP-9 [68] . According to metabolic effects of oral estrogen are very different from this hypothesis, acute administration may be harmful, and those of non-oral (e.g. transdermal) estrogen; the latter is chronic administration may be beneficial. Estrogen demore likely to mimic the effects of endogenous estrogen, creases PAI-1 levels and increases plasmin activity, which and thus may be more informative about the mechanisms in turn increases the expression of MMP-9. Local elevaunderlying the gender difference in CHD. More studies on tions of matrix metalloproteinases in the vulnerable plaque the effects of non-oral estrogens are needed, including are associated with weakening and rupture of the thin trials with clinical outcomes. fibrous cap, which is thought to precipitate the thrombotic It is possible, but unproven, that in part the gender occlusion of the vessel [69] . Thus, the acute effect of HRT difference may be due to adverse effects of androgens in might be unfavorable in women with vulnerable plaques.
men, and more studies of androgens, antiandrogens, and 
